These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3134928)

  • 1. Tuberculosis prevention: cost-effectiveness analysis of isoniazid chemoprophylaxis.
    Rose DN; Schechter CB; Fahs MC; Silver AL
    Am J Prev Med; 1988; 4(2):102-9. PubMed ID: 3134928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
    Salpeter SR; Sanders GD; Salpeter EE; Owens DK
    Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors.
    Rose DN; Schechter CB; Silver AL
    JAMA; 1986 Nov; 256(19):2709-13. PubMed ID: 3773178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors.
    Colice GL
    Arch Intern Med; 1990 Dec; 150(12):2517-22. PubMed ID: 2244768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid preventive therapy in areas of high isoniazid resistance.
    Sterling TR; Brehm WT; Frieden TR
    Arch Intern Med; 1995 Aug 7-21; 155(15):1622-8. PubMed ID: 7618985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoniazid chemoprophylaxis of tuberculosis.
    Jenkins D; Davidson FF
    Calif Med; 1972 Apr; 116(4):1-5. PubMed ID: 5019090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.
    Selwyn PA; Sckell BM; Alcabes P; Friedland GH; Klein RS; Schoenbaum EE
    JAMA; 1992 Jul 22-29; 268(4):504-9. PubMed ID: 1619742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.
    Jordan TJ; Lewit EM; Montgomery RL; Reichman LB
    JAMA; 1991 Jun; 265(22):2987-91. PubMed ID: 2033771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
    Salpeter SR
    West J Med; 1993 Nov; 159(5):560-4. PubMed ID: 8279152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid for the tuberculin reactor: take it or leave it.
    Tsevat J; Taylor WC; Wong JB; Pauker SG
    Am Rev Respir Dis; 1988 Jan; 137(1):215-20. PubMed ID: 3276255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.
    Gourevitch MN; Hartel D; Selwyn PA; Schoenbaum EE; Klein RS
    AIDS; 1999 Oct; 13(15):2069-74. PubMed ID: 10546859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors.
    Moulding T
    Arch Intern Med; 1991 Oct; 151(10):2101, 2105. PubMed ID: 1929702
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis.
    Salpeter SR; Salpeter EE
    Infect Control Hosp Epidemiol; 2004 Dec; 25(12):1056-61. PubMed ID: 15636292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
    Gourevitch MN; Alcabes P; Wasserman WC; Arno PS
    Int J Tuberc Lung Dis; 1998 Jul; 2(7):531-40. PubMed ID: 9661818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuberculin screening: cost-effectiveness analysis of various testing schedules.
    Schechter CB; Rose DN; Fahs MC; Silver AL
    Am J Prev Med; 1990; 6(3):167-75. PubMed ID: 2118787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The competing risks of tuberculosis and hepatitis for adult tuberculin reactors.
    Comstock GW; Edwards PQ
    Am Rev Respir Dis; 1975 May; 111(5):573-7. PubMed ID: 1130750
    [No Abstract]   [Full Text] [Related]  

  • 17. Modern trends in chemoprophylaxis in tuberculosis.
    Hubaytar R
    J Med Liban; 1973; 26(2):89-93. PubMed ID: 4581836
    [No Abstract]   [Full Text] [Related]  

  • 18. Underutilization of isoniazid chemoprophylaxis in tuberculosis contacts 50 years of age and older. A prospective analysis.
    Sorresso DJ; Mehta JB; Harvill LM; Bentley S
    Chest; 1995 Sep; 108(3):706-11. PubMed ID: 7656620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test.
    Fitzgerald JM; Gafni A
    Am Rev Respir Dis; 1990 Oct; 142(4):848-53. PubMed ID: 2121080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.